Allergy

Biosimilars

Cardiology

Dermatology

Endocrinology

Family Medicine

Gastroenterology

Geriatrics

Hospital Medicine

Infectious Disease

Internal Medicine

Nephrology

Neurology

Obesity Management

Ophthalmology

Pain

Pediatrics

Psychiatry

Pulmonology

Rare Disease Report®

Rheumatology

Sleep

Surgery

Women's Health

News

Media

Medical World News

Podcasts

Shows

State Of Sciences - Presentations

Videos

Webinars

Multimedia Series

Insights

Medcast Podcasts

Medcast Videos

Peer Exchange

Peers & Perspectives

Conferences

Conference Coverage

Conference Listing

Partners

CME/CE

Resources

Interactive Tools

Live Events

Press Release

Publications

Subscribe

Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.

Articles

Results may help minimize the risk of developing hyperuricemia, gout, and related adverse events in patients receiving antihypertensive drugs.

Certain Antihypertensive Drugs may Increase Risk of Hyperuricemia, Gout

The positivity rate of rhinoviruses and enteroviruses decreased briefly following the onset of the COVID-19 pandemic, but by fall of 2020 resumed almost to pre-pandemic levels. 

Acute Respiratory Illness in Pediatric Patients Before and During COVID-19 Pandemic

Connor Iapoce is an associate editor for 

 and joined the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to concerts, and playing with his cat Squish. You can reach him at 

New 6-month findings from a First-in-Human glaucoma treatment trial indicate the drug delivery platform continued to show a 45% reduction in mean intraocular pressure. 

Malik Kahook, MD: Updates on SpyGlass Platform for Glaucoma Treatment

Brian LaMoreaux, MD, MS, is a rheumatologist and Senior Medical Director at Horizon Therapeutics. 

As an industry and a society, we must take gout more seriously. That effort begins with the physicians who diagnose and treat it. 

Gout Isn’t a Punchline. It’s Time to Stop Treating it Like One. 

HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors, and more.

About Us

Advertise

Editorial

Contact Us

Do Not Sell My Information

Privacy

Terms & Conditions

HCPLive - Clinical news for connected physicians

Facebook

Twitter

LinkedIn

Spotlight

Biosimilars Spotlight

COVID-19

Qazi Corner

This Year In Medicine 2022

Clinical

ADHD

Arterial Disease

Diabetes

Geriatric Medicine

Video Series

News Network

Post Conference Perspectives

 News Network page is a resource for live video interviews with leading clinical experts and investigators from major medical conferences and events throughout the year.

Dermatologists Drs Neal Bhatia and Dr Leon Kircik discuss topical treatments and how recent approval of a novel topical PDE4 inhibitor is likely to impact the treatment landscape of plaque psoriasis.

PDE4 Inhibitors in Treatment of Plaque Psoriasis

David P. Hudesman, shares insight on long-term extension data and clinical implications from ACG 2022 on the use of ustekinumab for the management of ulcerative colitis.

Four-Year Efficacy and Safety Data of Ustekinumab Use in Ulcerative Colitis

Insight from gastroenterology specialists on implications for treating patients with ulcerative colitis with newer novel therapies as recently presented at DDW 2021.

Emerging Therapies for the Management of Ulcerative Colitis

Advancing Long-Term Arthritis Care at ACR 2020

Optimal Management of Rheumatic Disease During COVID-19

Early Initiation With LAIs to Optimally Manage Schizophrenia